Hun Ju Lee, MD The University of Texas MD Anderson Cancer Center 5Live #ASCO2020
5:08
Key Insights on Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL)
Mantle Cell Lymphoma
Hun Ju Lee, MD The University of Texas MD Anderson Cancer Center 5Live #ASCO2020
Key Insights on Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL)
Mantle Cell Lymphoma Similar Videos
Similar Videos
